

# Alain Ravaud

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2134001/alain-ravaud-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

210  
papers

22,888  
citations

51  
h-index

150  
g-index

236  
ext. papers

27,710  
ext. citations

8.5  
avg, IF

6.29  
L-index

#	Paper	IF	Citations
210	Development of an evidence-based reference framework for care coordination with a focus on the micro level of integrated care: A mixed method design study combining scoping review of reviews and nominal group technique.. <i>Health Policy</i> , <b>2022</b> , 126, 245-245	3.2	0
209	Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression. <i>Molecular Cancer</i> , <b>2021</b> , 20, 136	42.1	2
208	Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. <i>European Journal of Cancer</i> , <b>2021</b> , 157, 474-484	7.5	5
207	Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review. <i>European Journal of Cancer</i> , <b>2021</b> , 158, 47-62	7.5	7
206	An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. <i>Nature Medicine</i> , <b>2021</b> , 27, 793-801	50.5	18
205	Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF- $\beta$ and PD-L1, in advanced squamous cell carcinoma of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 6020-6020	2.2	1
204	Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. <i>European Urology</i> , <b>2021</b> , 79, 665-673	10.2	1
203	Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial. <i>European Urology Oncology</i> , <b>2021</b> , 4, 456-463	6.7	4
202	Colitis presenting 5 months after the final dose of anti-PD-1: long-term monitoring is warranted after adjuvant therapy. <i>Immunotherapy</i> , <b>2021</b> , 13, 741-744	3.8	0
201	Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives. <i>Cancer Treatment Reviews</i> , <b>2021</b> , 97, 102207	14.4	4
200	VOTRAGE study: Phase I dose-escalation study of pazopanib in unfit older patients. <i>Journal of Geriatric Oncology</i> , <b>2021</b> , 12, 759-764	3.6	2
199	Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial. <i>European Urology</i> , <b>2021</b> , 80, 7-11	10.2	12
198	Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. <i>European Urology</i> , <b>2021</b> , 79, 659-662	10.2	30
197	Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting. <i>Future Oncology</i> , <b>2021</b> , 17, 403-409	3.6	1
196	Estimand framework: Are we asking the right questions? A case study in the solid tumor setting. <i>Pharmaceutical Statistics</i> , <b>2021</b> , 20, 324-334	1	3
195	Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 78-86	12.9	60
194	Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?. <i>European Urology Oncology</i> , <b>2021</b> , 4, 274-281	6.7	5

193	Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma. <i>Communications Biology</i> , <b>2021</b> , 4, 166	6.7	4
192	The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumours. <i>Acta Oncologica</i> , <b>2021</b> , 60, 1597-1603	3.2	2
191	Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?. <i>European Urology</i> , <b>2021</b> , 80, 417-424	10.2	11
190	Safety of sunitinib in patients with renal cell carcinoma following nephrectomy. <i>Expert Opinion on Drug Safety</i> , <b>2020</b> , 19, 799-806	4.1	0
189	Adaptation of multidisciplinary meeting decisions in a medical oncology department during the COVID epidemic in a less affected region of France: a prospective analysis from Bordeaux University Hospital. <i>European Journal of Cancer</i> , <b>2020</b> , 135, 98-100	7.5	0
188	Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4863-4868	12.9	6
187	Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2020</b> , 86, 97-108	3.5	0
186	Exploring Biological Predictive Factors of Progression After Surgery in High-Risk Renal Cell Carcinoma: Results From the French Cohort of the Randomized S-TRAC Trial Patients. <i>Frontiers in Surgery</i> , <b>2020</b> , 7, 26	2.3	1
185	Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial. <i>European Journal of Cancer</i> , <b>2020</b> , 129, 107-116	7.5	19
184	The official French guidelines to protect patients with cancer against SARS-CoV-2 infection. <i>Lancet Oncology</i> , <b>2020</b> , 21, 619-621	21.7	107
183	Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment. <i>British Journal of Clinical Pharmacology</i> , <b>2020</b> , 86, 1807-1818	3.8	2
182	A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment. <i>Pharmacology Research and Perspectives</i> , <b>2020</b> , 8, e00613	3.1	1
181	Open-label randomized multi-center phase 2 study: gemcitabine cisplatin plus avelumab or gemcitabine cisplatin as first-line treatment of patients with locally advanced or metastatic urothelial bladder carcinoma: GCisAve. <i>Bulletin Du Cancer</i> , <b>2020</b> , 107, eS1-eS7	2.4	2
180	Bintrafusp alfa, a bifunctional fusion protein targeting TGF- $\beta$ and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort <b>2020</b> , 8,		23
179	Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study. <i>European Journal of Cancer</i> , <b>2020</b> , 136, 76-83	7.5	9
178	Prognostic factors for cancer patient admitted to a medical intensive care unit. <i>Acta Oncologica</i> , <b>2020</b> , 59, 458-461	3.2	3
177	Atezolizumab for the treatment of renal cell carcinoma. <i>Expert Opinion on Biological Therapy</i> , <b>2020</b> , 20, 679-686	5.4	
176	Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer. <i>European Urology</i> , <b>2020</b> , 77, 269-276	10.2	24

175	The development of a regional referral pathway for locally recurrent rectal cancer: A Delphi consensus study. <i>European Journal of Surgical Oncology</i> , <b>2020</b> , 46, 470-475	3.6	0
174	Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis <b>2020</b> , 8,		18
173	Management of Immune Checkpoint Inhibitor Toxicities. <i>Cancer Management and Research</i> , <b>2020</b> , 12, 9139-9158	3.6	6
172	Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study). <i>BJU International</i> , <b>2020</b> , 126, 559-567	5.6	1
171	Current management and future perspectives of penile cancer: An updated review. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 90, 102087	14.4	10
170	Long-term prognosis of septic shock in cancer patients. <i>Supportive Care in Cancer</i> , <b>2020</b> , 28, 1325-1333	3.9	6
169	Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. <i>BJU International</i> , <b>2020</b> , 126, 73-82	5.6	7
168	Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2019</b> , 5, 623-632	13.4	13
167	The interest of sequential treatment with immune check point inhibitors followed chemotherapy: A case report. <i>Oral Oncology</i> , <b>2019</b> , 94, 125-127	4.4	1
166	Successful Treatment of Metastatic Adult Wilms Tumor With Anti-BRAF Treatment: A Case Report and a Brief Review of the Literature. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, e721-e723	3.3	3
165	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. <i>Lancet, The</i> , <b>2019</b> , 393, 2404-2415	4.0	490
164	Metastatic Clear-cell Renal Cell Carcinoma With a Long-term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 Expression. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, 169-176.e1	3.3	2
163	Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment. <i>Clinical Pharmacokinetics</i> , <b>2019</b> , 58, 1165-1174	6.2	6
162	Which place for avelumab in the management of urothelial carcinoma?. <i>Expert Opinion on Biological Therapy</i> , <b>2019</b> , 19, 863-870	5.4	3
161	Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial <b>2019</b> , 7, 275		28
160	Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. <i>Nature Medicine</i> , <b>2019</b> , 25, 1706-1714	50.5	193
159	Renal cell carcinoma lung metastases treated by radiofrequency ablation integrated with systemic treatments: over 10 years of experience. <i>BMC Cancer</i> , <b>2019</b> , 19, 1182	4.8	12
158	Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 1165-1173	12.9	10

157	Dramatic response under combination of immune-oncology in head & neck cancer included in the Condor study: A case report. <i>Oral Oncology</i> , <b>2019</b> , 89, 150-152	4.4	
156	Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, e150-e162	3.8	2
155	Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 1554-1561	12.9	26
154	Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. <i>Lancet, The</i> , <b>2018</b> , 391, 748-757	40	753
153	Alterations in comprehensive geriatric assessment decrease survival of elderly patients with cancer. <i>European Journal of Cancer</i> , <b>2018</b> , 90, 10-18	7.5	18
152	Progression beyond nivolumab: Stop or repeat? Dramatic responses with salvage chemotherapy. <i>Oral Oncology</i> , <b>2018</b> , 81, 116-118	4.4	13
151	Treatment of spinal metastases in renal cell carcinoma: A critical review. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 125, 19-29	7	7
150	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 1277-1290	59.2	2064
149	Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial. <i>European Urology</i> , <b>2018</b> , 73, 696-703	10.2	33
148	Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. <i>European Urology</i> , <b>2018</b> , 73, 62-68	10.2	95
147	Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 5534-5542	12.9	10
146	Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma. <i>Theranostics</i> , <b>2018</b> , 8, 2447-2458	12.1	8
145	Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 417-427	59.2	416
144	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. <i>Nature Medicine</i> , <b>2018</b> , 24, 749-757	50.5	558
143	A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4506-4506	2.2	62
142	Neutrophil-to-lymphocyte ratio as a potential prognostic factor of disease-free survival in high-risk renal cell carcinoma: Analysis of the S-TRAC trial.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4562-4562	2.2	1
141	CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—Results of a phase III noninferiority trial.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, LBA3-LBA3	2.2	6
140	IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC). <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 578-578	2.2	140

139	Disease-free survival in patients at highest risk of recurrent renal cell carcinoma in S-TRAC.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4565-4565	2.2	
138	Prognostic factors in critically ill patients with solid cancer admitted to medical intensive care unit.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e18745-e18745	2.2	
137	Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 51-64 <sup>21.7</sup>	362	
136	Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 393-398	2.4	162
135	Reply to Francesco Massari, Vincenzo Di Nunno, and Andrea Ardizzoni@ Letter to the Editor re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. <i>Eur Urol</i> <b>2018</b> ;73:62-8. <i>European Urology</i> , <b>2018</b> , 73, e73	10.2	1
134	Adjuvant therapy after nephrectomy for renal cell carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2018</b> , 14 Suppl 5, 33-36	1.9	0
133	Dramatic response after anti PD1 treatment failure in a squamous cell carcinoma of the maxillary sinus. <i>Oral Oncology</i> , <b>2018</b> , 87, 207-209	4.4	2
132	Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4407-4415	12.9	29
131	Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas. <i>Cancer Research</i> , <b>2017</b> , 77, 1212-1226	10.1	54
130	Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. <i>European Urology</i> , <b>2017</b> , 72, 368-376	10.2	148
129	Relationship between Pulmonary Adverse Events and Everolimus Exposure in Japanese and Non-Japanese Patients: A Meta-Analysis of Oncology Trials. <i>Oncology</i> , <b>2017</b> , 92, 243-254	3.6	3
128	Pulmonary arterial hypertension due to an intratumoral shunt: an unexpected side effect of sunitinib. <i>Future Oncology</i> , <b>2017</b> , 13, 1219-1221	3.6	0
127	A prospective observational study on the evaluation of everolimus-related adverse events in metastatic renal cell carcinoma after first-line anti-vascular endothelial growth factor therapy: the AFINITE study in France. <i>Supportive Care in Cancer</i> , <b>2017</b> , 25, 2055-2062	3.9	4
126	Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2017</b> , 26, 1561-1569 <sup>14</sup>	2.6	14
125	Drug Interaction With Sunitinib and the Evidence of Therapeutic Drug Monitoring: A Case Report and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, e885-e887	3.3	2
124	Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy. <i>Targeted Oncology</i> , <b>2017</b> , 12, 487-494	5	23
123	A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. <i>European Journal of Cancer</i> , <b>2017</b> , 76, 110-117	7.5	63
122	Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study. <i>BJU International</i> , <b>2017</b> , 119, 846-853	5.6	3

121	Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2117-2124	2.2	415
120	Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study. <i>European Journal of Cancer</i> , <b>2017</b> , 85, 39-48	7.5	2
119	Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatment. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 603.e7-603.e14	2.8	14
118	Immune checkpoint inhibitors and elderly people: A review. <i>European Journal of Cancer</i> , <b>2017</b> , 82, 155-166	7.5	99
117	Immunotherapy in head and neck cancer: Need for a new strategy? Rapid progression with nivolumab then unexpected response with next treatment. <i>Oral Oncology</i> , <b>2017</b> , 64, e1-e3	4.4	11
116	Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort. <i>Targeted Oncology</i> , <b>2016</b> , 11, 83-92	5	2
115	Targeted therapy and elderly people: A review. <i>European Journal of Cancer</i> , <b>2016</b> , 69, 199-215	7.5	22
114	Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, 406-414	3.3	8
113	Are we ready for day-case partial nephrectomy?. <i>World Journal of Urology</i> , <b>2016</b> , 34, 883-7	4	7
112	Randomized Open-Label Phase II Trial of Apatolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1660-8	2.2	68
111	Efficacy of Rechallenge of Metastatic Renal Cell Carcinoma Patient With Sunitinib After Prior Resistance to Axitinib: Case Report and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, e525-e527	3.3	1
110	Effectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: Results of the ETNA observational cohort. <i>Journal of Geriatric Oncology</i> , <b>2016</b> , 7, 187-94	3.6	11
109	m-TOR inhibitor as potential radiosensitizer for head and neck squamous cell carcinoma: A case report of an organ transplant patient and review of the literature. <i>Oral Oncology</i> , <b>2016</b> , 62, e1-e2	4.4	2
108	Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 2246-2254	59.2	450
107	Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 339.e9-15	2.8	45
106	Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model. <i>European Urology</i> , <b>2015</b> , 68, 196-204	10.2	79
105	Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1803-13	59.2	3725
104	Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3431-8	2.2	44

103	Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project <i>Annals of Oncology</i> , <b>2015</b> , 26, 2392-8	10.3	22
102	Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 787-94	21.7	155
101	Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study. <i>BJU International</i> , <b>2015</b> , 115, 65-73	5.6	4
100	Toxicity Management of Renal Cell Cancer Patients on Targeted Therapies <b>2015</b> , 365-384		
99	Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort. <i>Targeted Oncology</i> , <b>2014</b> , 9, 311-9	5	19
98	A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases. <i>Clinical Genitourinary Cancer</i> , <b>2014</b> , 12, 50-4	3.3	51
97	Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literature. <i>Targeted Oncology</i> , <b>2014</b> , 9, 81-4	5	3
96	Pulmonary aspergilloma: an unexpected complication of radiofrequency ablation in the management of targeted therapy for a patient with metastatic renal cell carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2014</b> , 12, e115-6	3.3	1
95	Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). <i>European Journal of Cancer</i> , <b>2014</b> , 50, 953-62	7.5	52
94	Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms. <i>Expert Opinion on Drug Safety</i> , <b>2014</b> , 13, 361-72	4.1	26
93	Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib. <i>Acta Oncologica</i> , <b>2014</b> , 53, 1413-22	3.2	24
92	How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I study. <i>British Journal of Clinical Pharmacology</i> , <b>2014</b> , 77, 498-508	3.8	8
91	Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 3012-22	12.9	43
90	Protein kinase inhibitors in renal cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , <b>2014</b> , 15, 337-51	4	7
89	Relationship between everolimus exposure and safety and efficacy: meta-analysis of clinical trials in oncology. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 486-95	7.5	55
88	Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 149-58	21.7	415
87	Emerging antiangiogenics for renal cancer. <i>Expert Opinion on Emerging Drugs</i> , <b>2013</b> , 18, 495-511	3.7	15
86	Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial. <i>Clinical Genitourinary Cancer</i> , <b>2013</b> , 11, 128-33	3.3	13



85	Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications. <i>Cancer Treatment Reviews</i> , <b>2013</b> , 39, 784-92	14.4	22
84	Therapy management with sunitinib in patients with metastatic renal cell carcinoma: key concepts and the impact of clinical biomarkers. <i>Cancer Treatment Reviews</i> , <b>2013</b> , 39, 230-40	14.4	19
83	What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?. <i>Cancer Treatment Reviews</i> , <b>2013</b> , 39, 366-74	14.4	27
82	Combination therapy in metastatic renal cell cancer. <i>Seminars in Oncology</i> , <b>2013</b> , 40, 472-81	5.5	18
81	The experimental renal cell carcinoma model in the chick embryo. <i>Angiogenesis</i> , <b>2013</b> , 16, 181-94	10.6	38
80	The role of surgery for metastatic renal cell carcinoma in the era of targeted therapies. <i>World Journal of Urology</i> , <b>2013</b> , 31, 1383-8	4	8
79	Functional decline in older patients with cancer receiving first-line chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3877-82	2.2	152
78	Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma. <i>Clinical Medicine Insights: Oncology</i> , <b>2013</b> , 7, 269-77	1.8	51
77	Optimal management of renal cell carcinoma in the elderly: a review. <i>Clinical Interventions in Aging</i> , <b>2013</b> , 8, 433-42	4	21
76	Real-life patterns of use and effectiveness of sunitinib in patients with metastatic renal cell carcinoma: The SANTORIN study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 400-400	2.2	3
75	Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. <i>European Urology</i> , <b>2012</b> , 61, 826-33	10.2	51
74	Editorial comment to therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma. <i>International Journal of Urology</i> , <b>2012</b> , 19, 805	2.3	2
73	Targeted therapies in metastatic renal cell carcinoma: overview of the past year. <i>Current Urology Reports</i> , <b>2012</b> , 13, 16-23	2.9	15
72	Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies. <i>Cancer Treatment Reviews</i> , <b>2012</b> , 38, 127-32	14.4	6
71	A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 209-17 <sup>5</sup>	7.5	36
70	Overcoming resistance to tyrosine kinase inhibitors in renal cell carcinoma. <i>Cancer Treatment Reviews</i> , <b>2012</b> , 38, 996-1003	14.4	36
69	Quitter enfin des mauvais résultats de la chimiothérapie dans le cancer du pancréas métastatique grâce à un groupe coopératif français. <i>Bulletin Du Cancer</i> , <b>2012</b> , 99, 405	2.4	
68	AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. <i>Cancer</i> , <b>2012</b> , 118, 6152-61	6.4	89

67	Experience with sunitinib in the treatment of metastatic renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , <b>2012</b> , 4, 253-65	3.2	27
66	Lapatinib and renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , <b>2012</b> , 21, 1727-32	5.9	3
65	Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1829-34	2.2	294
64	Safety and efficacy of AMG 386 in combination with sunitinib in patients with metastatic renal cell carcinoma (mRCC) in an open-label multicenter phase II study.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4606-4606	2.2	4
63	Tivozanib: is total VEGFR inhibition the way to success in terms of tolerability and efficacy in advanced kidney cancer?. <i>Translational Andrology and Urology</i> , <b>2012</b> , 1, 197-8	2.3	
62	Toxicity Management of Renal Cell Cancer Patients on Targeted Therapies <b>2012</b> , 265-283		
61	Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 1287-98	7.5	118
60	Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2011</b> , 29, 4-11	2.8	18
59	Exposure-response relationships in patients with metastatic renal cell carcinoma receiving sunitinib: maintaining optimum efficacy in clinical practice. <i>Anti-Cancer Drugs</i> , <b>2011</b> , 22, 377-83	2.4	14
58	Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon- $\alpha$ and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial. <i>BJU International</i> , <b>2011</b> , 107, 214-9	5.6	37
57	Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urothelium unfit for cisplatin-based chemotherapy: a randomized phase 2 study of the French Genitourinary Tumor Group (GETUG V01). <i>European Urology</i> , <b>2011</b> , 60, 1251-7	10.2	24
56	Lung tumors treated with percutaneous radiofrequency ablation: computed tomography imaging follow-up. <i>CardioVascular and Interventional Radiology</i> , <b>2011</b> , 34, 989-97	2.7	52
55	Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors. <i>Acta Oncologica</i> , <b>2011</b> , 50, 1135-6	3.2	7
54	Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. <i>Oncologist</i> , <b>2011</b> , 16 Suppl 2, 32-44	5.7	67
53	EGF receptor inhibitors <b>2011</b> , 68-78		
52	Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU. <i>Oncologist</i> , <b>2010</b> , 15, 212-3; author reply 214	5.7	50
51	Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2144-50	2.2	669
50	Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2010</b> , 182, 396-403	10.2	169

49	Amplification of epidermal growth factor receptor gene in renal cell carcinoma. <i>European Journal of Cancer</i> , <b>2010</b> , 46, 859-62	7.5	10
48	Therapeutic management of de novo urological malignancy in renal transplant recipients: the experience of the French Department of Urology and Kidney Transplantation from Bordeaux. <i>Urology</i> , <b>2010</b> , 75, 126-32	1.6	51
47	The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2010</b> , 28, 473-9	2.8	88
46	Metronomic chemotherapy for renal cancer in the landscape of targeted therapy. <i>Lancet Oncology, The</i> , <b>2010</b> , 11, 307-8	21.7	2
45	Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice. <i>Cancer Investigation</i> , <b>2010</b> , 28, 856-64	2.1	30
44	Bladder cancer in patients after organ transplantation. <i>Current Opinion in Urology</i> , <b>2010</b> , 20, 432-6	2.8	9
43	Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. <i>Cancer</i> , <b>2010</b> , 116, 4256-65	6.4	904
42	Tyrosine-kinase inhibitors in the treatment of muscle invasive bladder cancer and hormone refractory prostate cancer. <i>Archivos Espanoles De Urologia</i> , <b>2010</b> , 63, 773-87	0.4	4
41	Case study of the month. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma. <i>European Urology</i> , <b>2009</b> , 55, 1477-80	10.2	50
40	Laparoscopic radical prostatectomy in renal transplant recipients. <i>Urology</i> , <b>2009</b> , 74, 683-7	1.6	27
39	Molecular Pathways in Metastatic Renal Cell Carcinoma: The Evolving Role of Mammalian Target of Rapamycin Inhibitors. <i>European Urology Supplements</i> , <b>2009</b> , 8, 793-798	0.9	3
38	Current and Future Treatment Options for Metastatic Renal Cell Carcinoma. <i>European Urology Supplements</i> , <b>2009</b> , 8, 799-808	0.9	3
37	Mammalian Target of Rapamycin Inhibitors in Clinical Practice: Case Reports of Everolimus in Renal Cell Carcinoma. <i>European Urology Supplements</i> , <b>2009</b> , 8, 815-819	0.9	1
36	Update on the medical treatment of metastatic renal cell carcinoma. <i>European Urology</i> , <b>2008</b> , 54, 315-25	10.2	40
35	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. <i>Lancet, The</i> , <b>2008</b> , 372, 449-56	40	2451
34	Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 2285-91	2.2	80
33	Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 5907-12	12.9	20
32	Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 127-31	2.2	328

31	Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways. <i>Current Opinion in Urology</i> , <b>2008</b> , 18, 524-32	2.8	34
30	Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. <i>Cancer</i> , <b>2007</b> , 110, 2468-77	6.4	160
29	Cutaneous cryptococcosis with alemtuzumab in a patient treated for chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , <b>2007</b> , 137, 490	4.5	10
28	Epithelial growth factor receptor (EGFR) pathway and renal cell carcinoma. <i>Targeted Oncology</i> , <b>2007</b> , 2, 99-105	5	3
27	Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. <i>Lancet, The</i> , <b>2007</b> , 370, 2103-11	40	1856
26	Targeted therapy in metastatic renal cell carcinoma: efficacy, adverse-event management and key considerations. <i>European Journal of Cancer, Supplement</i> , <b>2007</b> , 5, 1-3	1.6	1
25	Current options for the treatment of locally advanced and metastatic renal cell carcinoma: focus on sunitinib. <i>European Journal of Cancer, Supplement</i> , <b>2007</b> , 5, 4-11	1.6	2
24	Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse-event management. <i>European Journal of Cancer, Supplement</i> , <b>2007</b> , 5, 12-19	1.6	19
23	Key considerations in patient selection for the use of targeted therapy in metastatic renal cell carcinoma. <i>European Journal of Cancer, Supplement</i> , <b>2007</b> , 5, 20-27	1.6	4
22	Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. <i>Journal of Urology</i> , <b>2007</b> , 178, 1901-5	2.5	53
21	Méastases vertébrales des cancers du rein <b>2007</b> , 155-163		
20	Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. <i>Radiology</i> , <b>2006</b> , 240, 587-96	20.5	291
19	Interferon alpha for the treatment of advanced renal cancer. <i>Expert Opinion on Biological Therapy</i> , <b>2005</b> , 5, 749-62	5.4	10
18	Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. <i>World Journal of Urology</i> , <b>2005</b> , 23, 161-5	4	42
17	Current Strategy in the Treatment of Metastatic Renal Cell Carcinoma. <i>Current Cancer Therapy Reviews</i> , <b>2005</b> , 1, 127-137	0.4	1
16	Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Français d'Immunothérapie. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 2371-8	2.2	142
15	Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. <i>Brain, Behavior, and Immunity</i> , <b>2004</b> , 18, 205-13	16.6	195
14	Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma--Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie. <i>Cancer</i> , <b>2002</b> , 95, 2324-30	6.4	20

13	Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. <i>Psychoneuroendocrinology</i> , <b>2001</b> , 26, 797-808	5	168
12	Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients. <i>Psychosomatic Medicine</i> , <b>2001</b> , 63, 376-86	3.7	111
11	Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 2143-51	2.2	245
10	Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérapie. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 2039-43	2.2	78
9	Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. <i>New England Journal of Medicine</i> , <b>1999</b> , 340, 1370	59.2	134
8	Present achievements in the medical treatment of metastatic renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , <b>1999</b> , 31, 77-87	7	12
7	Taxane-induced glaucoma. <i>Lancet, The</i> , <b>1999</b> , 354, 1181-2	40	19
6	Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. <i>New England Journal of Medicine</i> , <b>1998</b> , 338, 1272-8	59.2	783
5	Phase II study of interferon-alpha and all-trans retinoic acid in metastatic renal cell carcinoma. <i>Journal of Immunotherapy</i> , <b>1998</b> , 21, 62-4	5	11
4	A survey in general practice about undergraduate cancer education: results from Gironde (France). <i>Journal of Cancer Education</i> , <b>1991</b> , 6, 153-7	1.8	9
3	Cancer chemotherapy in the elderly: a series of 51 patients aged greater than 70 years. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1991</b> , 29, 159-63	3.5	17
2	Metastatic Renal Cell Carcinoma 387-394		
1	An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives. <i>Therapeutics and Clinical Risk Management</i> , Volume 18, 619-632	2.9	0